MCM
COGT icon

Moore Capital Management’s Cogent Biosciences COGT Stock Holding History

Moore Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-118,266
Closed -$995K – 757
2021
Q3 		$995K Sell
118,266
-3,519
-3% -$27K 0.02% 508
2021
Q2 		$988K Sell
121,785
-1,861
-2% -$15.7K 0.01% 532
2021
Q1 		$1.09M Buy
123,646
+10,616
+9% +$102K 0.01% 500
2020
Q4 		$1.27M Buy
+113,030
New +$1.24M 0.01% 394

Other funds holding COGT

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Moore Capital Management's COGT Position: Q4 2021 in Review

Moore Capital Management sold out of Cogent Biosciences (COGT) in Q4 2021, closing a stake of 118,266 shares — an estimated $995K sold.

Moore Capital Management first reported a position in COGT in Q4 2020 and held it in 4 quarters. The position peaked at $1.27M in Q4 2020. 82 funds tracked by Wall St. Rank hold COGT as of Q4 2021.

  • Moore Capital Management reported no remaining Cogent Biosciences position as of Q4 2021 after selling out during the quarter.
  • Moore Capital Management sold 118,266 Cogent Biosciences shares in Q4 2021, an estimated $995K.
  • Moore Capital Management first reported a position in Cogent Biosciences in Q4 2020 and held it in 4 quarters.
  • Moore Capital Management's Cogent Biosciences position peaked at $1.27M in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.